On the Leading Edge of Discovery

Neurotrope, Inc. (Symbol: NTRP) is a specialty biopharmaceutical company developing new therapeutics for the treatment of rare diseases (Orphan diseases) and Alzheimer’s Disease.

NTRP has advanced two other Orphan Disease programs using Bryostatin. We are working with the Ichan School of Medicine at Mt. Sinai Hospital in New York to determine the efficacy of Bryostatin-1 for the treatment of Niemann Pick Disease, Type C. In addition, we are also working with the FRAXA Research Foundation to help find a treatment for Fragile X Syndrome using Bryostatin-1.

NTRP licensed the use of Bryostatin-1 for the treatment of Alzheimer’s Disease as well as other neurodegenerative diseases from the Blanchette Rockefeller Neuroscience Institute (BRNI). To date NTRP has successfully completed a first Phase 2 study in moderate Alzheimer’s patients. We are now planning to start a second Phase 2 study.

NTRP has also teamed up with Stanford University to find the next generation Bryostatin – Bryologs.

NTRP is also progressing the other licensed asset from BRNI – a new, non-invasive diagnostic test for early stage Alzheimer’s Disease.

Activation of PKCe is believed to have a multimodal effect in reversing the key pathological processes that lead to the development of Alzheimer’s Disease. Drugs effective in activating PKCe could delay the progression of Alzheimer’s Disease and possibly restore cognitive and memory functions already damaged by the disease

Synaptogenesis: Stimulating the Formation of Synapses between Neurons in the Nervous System

Through the acquisition of the rights to the BRNI developed technology, NTRP is pioneering a new approach for the treatment of neurodegenerative disease through the activation of protein kinase C-epsilon (PKCε). The BRNI scientists demonstrated that the selective activation of the PKC enzyme was effective in improving memory and cognition disorders stemming from neurodegenerative disease in animal models. This approach exploits a complex pathway of biochemical events in the neuron that seem to be centrally orchestrated by PKCε. The changes mediated by PKCε effectively converge in reversing the neuronal damage and loss central to the pathogenic process in Alzheimer’s Disease. NTRP is advancing these learnings into human clinical trials.

Presentation at Biotech Showcase 2015

Click here to view

Are you interested in being on our email list?

Click here to

sign up...